A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression

@article{Howland2011ABA,
  title={A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression},
  author={Robert H. Howland},
  journal={Drug Safety},
  year={2011},
  volume={34},
  pages={709-731}
}
  • R. Howland
  • Published 1 September 2011
  • Medicine
  • Drug Safety
Agomelatine is an antidepressant drug that is a synthetic analogue of the hormone melatonin. It stimulates the activity of melatonin MT1 and MT2 receptors and inhibits the activity of serotonin 5HT2C receptor subtypes.The objective of this article is to critically review and evaluate the benefits and risks of agomelatine for the treatment of major depression. The published literature through April 2011 for articles relating to agomelatine, together with unpublished data on agomelatine available… Expand
Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks
  • M. Gahr
  • Medicine
  • Current neuropharmacology
  • 2014
TLDR
Its unique mechanism of action with particular sleep modulating effects may represent a specific treatment strategy for patients with particular characteristics; further studies with thorough characterization of patients are needed to test this hypothesis. Expand
[Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability].
TLDR
The heterogeneous clinical manifestations of MDD and the unique mechanism of action of agomelatine with the ability of the drug to have a modulating effect on sleep, make it possible to effective use it for treating such disorders. Expand
Antidepressant efficacy of Agomelatine: Meta-analysis of placebo controlled and active comparator studies.
TLDR
This meta-analysis assesses the overall antidepressant effect of Agomelatine by pooling all the published and unpublished studies available till date to find an effective antidepressant having similar efficacy with the currently used antidepressants. Expand
The preclinical discovery and development of agomelatine for the treatment of depression
TLDR
There is now evidence supporting the clinical efficacy and safety profile of agomelatine in the acute-phase treatment of MDD, and findings of post-marketing research on safety, efficacy, and cost-effectiveness of the drug are examined. Expand
Agomelatine: a new option for treatment of depression?
  • C. Pae
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2014
TLDR
Based on currently available findings, agomelatine may not be recommendable as the first-line antidepressant for treating depression; especially, its putative benefits compared with other antidepressants must be thoroughly studied in adequately powered and well-designed future clinical trials. Expand
Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials.
TLDR
Evidence suggesting that a clinically important difference between agomelatine and placebo in patients with unipolar major depression is unlikely is found and there was evidence of substantial publication bias. Expand
Agomelatine for depression: expanding the horizons?
TLDR
Agomelatine is an antidepressant with unique pharmacological actions; it is both a melatonin agonist and selective serotonin antagonist and may have specific efficacy on symptoms of anhedonia. Expand
Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
TLDR
Current evidences on the role of agomelatine in disorders other than major depression are elucidated to point out a possible efficacy of such drug in the treatment of bipolar depression, anxiety disorders, alcohol dependence, migraines etc. Expand
Agomelatine: a review for general practitioners
TLDR
Agomelatine is a novel melatonergic antidepressant that restores disrupted biological rhythms, essentially by resetting the circadian clock, and represents an interesting addition to the antidepressant market. Expand
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
TLDR
Agomelatine is an effective antidepressant with similar efficacy to standard antidepressants. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Agomelatine Treatment of Major Depressive Disorder
TLDR
Overall, agomelatine is a promising and well-tolerated medication for the treatment of major depressive disorder and appears to be at least similar to some currently marketed antidepressants. Expand
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study
TLDR
It is demonstrated that agomelatine is efficient in the treatment of major depressive disorder and that 25 mg is the target dose. Expand
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
  • J. Olié, S. Kasper
  • Psychology, Medicine
  • The international journal of neuropsychopharmacology
  • 2007
TLDR
It is confirmed that agomelatine is effective in treating major depression, including the most severely depressed patients, with a good safety and tolerability profile, therefore providing physicians with an effective pharmacological approach to antidepressant therapy. Expand
Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study
TLDR
This study suggests that agomelatine is effective in the treatment of GAD and is well tolerated, and additional trials, using an active comparator and extending over a longer period, are needed to delineate the place of agomalatine in the contemporary pharmacotherapy for anxiety disorders. Expand
[Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders].
TLDR
Preliminary clinical data with agomelatine confirm the potential antidepressant effect in accordance with positive preclinical results, and suggest that 5 mg could be a at least as effective and slightly better tolerated dose than 100 mg. Expand
[Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders].
TLDR
Preliminary clinical data with agomelatine confirm the potential antidepressant effect in accordance with positive preclinical results, and suggest that 5 mg could be a dose at least as effective and slightly better tolerated than 100 mg. Expand
Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study
TLDR
In this study, agomelatine showed superior antidepressant efficacy over fluoxetine in treating patients with a severe episode of major depressive disorder after 8 weeks of treatment with a good tolerability profile. Expand
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
TLDR
The results support the prescription of agomelatine 25 mg as the usual therapeutic dose, and suggest that increasing the dose to 50 mg may be beneficial for some patients without reducing tolerability. Expand
Agomelatine in the treatment of seasonal affective disorder
TLDR
The results of this study suggest that seasonal depression may be effectively and safely treated with agomelatine. Expand
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
| Current management of major depression, a common and debilitating disorder with a high social and personal cost, is far from satisfactory. All available antidepressants act through monoaminergicExpand
...
1
2
3
4
5
...